United Therapeutics (UTHR) Revenue (2009 - 2026)

United Therapeutics has disclosed Revenue across 18 years of filings, most recently posting $783.3 million for Q2 2026.

• In Q2 2026, Revenue fell 1.92% year-over-year to $783.3 million; the TTM figure through Jun 2026 stood at $3.2 billion (up 2.49% YoY), while the FY2025 annual figure was $3.2 billion, up 10.61% from the prior year.
• Revenue came in at $783.3 million for Q2 2026 at United Therapeutics, roughly flat from $781.5 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $799.5 million in Q3 2025 to a low of $461.9 million in Q1 2022.
• Average Revenue over 5 years is $660.5 million, with a median of $696.3 million recorded in 2024.
• Year-over-year, Revenue soared 33.7% in 2024 and fell 1.92% in 2026.
• Over 5 years, Revenue stood at $491.5 million in 2022, then grew by 25.07% to $614.7 million in 2023, then climbed by 19.72% to $735.9 million in 2024, then grew by 7.38% to $790.2 million in 2025, then dropped by 0.87% to $783.3 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $783.3 million in Q2 2026, $781.5 million in Q1 2026, and $790.2 million in Q4 2025.